Summary
Treatment of choroidal melanoma by chemotherapy is usually unsuccessful, with response rates of less than 1% reported for dacarbazine (DTIC)-containing regimens which show 20% or more response rates in skin melanoma. Recently, we reported the activity of several cytotoxic agents against primary choroidal melanoma in an ATP-based tumour chemosensitivity assay (ATP-TCA). In this study, we have used the same method to examine the sensitivity of choroidal melanoma to combinations suggested by our earlier study. Tumour material from 36 enucleated eyes was tested against a battery of single agents and combinations which showed some activity in the previous study. The combination of treosulfan with gemcitabine or cytosine arabinoside showed consistent activity in 70% and 86% of cases, respectively. Paclitaxel was also active, particularly in combination with treosulfan (47%) or mitoxantrone (33%). Addition of paclitaxel to the combination of treosulfan + cytosine analogue added little increased sensitivity. For treosulfan + cytosine arabinoside, further sequence and timing experiments showed that simultaneous administration gave the greatest suppression, with minor loss of inhibition if the cytosine analogue was given 24 h after the treosulfan. Administration of cytosine analogue 24 h before treosulfan produced considerably less inhibition at any concentration. While we have so far been unable to study metastatic tumour from choroidal melanoma patients, the combination of treosulfan with gemcitabine or cytosine arabinoside shows activity ex vivo against primary tumour tissue. Clinical trials are in progress.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Albert, D. M., Niffenegger, A. S. & Willson, J. K. (1992). Treatment of metastatic uveal melanoma: a review and recommendations. Surv Ophthalmol 36: 429–438.
Albert, D. M., Ryan, L. M. & Borden, E. C. (1996). Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol, 114: 107–108.
Andreotti, P. E., Cree, I. A., Kurbacher, C. M., Hartmann, D. M., Linder, D., Harel, G., Gleiberman, I., Caruso, P. A., Ricks, S. H., Untch, M., Sartori, C. & Bruckner, H. W. (1995). Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res, 55: 5276–5282.
Bedikian, A. Y., Legha, S. S., Mavligit, G., Carrasco, C. H., Khorana, S., Plager, C., Papadopoulos, N. & Benjamin, R. S. (1995). Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer, 76: 1665–1670.
Cantore, M., Fiorentini, G., Aitini, E., Davitti, B., Cavazzini, G., Rabbi, C., Lusenti, A., Bertani, M., Morandi, C. & Benedini, V. (1994). Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori, 80: 37–39.
Chana, J. S., Cree, I. A., Foss, A. J. E., Hungerford, J. L. & Wilson, G. D. (1998). The prognostic significance of c-myc oncogene expression in uveal melanoma. Melanoma Res, 8: 139–144.
Cree, I. A., Kurbacher, C. M., Untch, M., Sutherland, L. A., Hunter, E. M. M., Subedi, A. M. C., James, E. A., Dewar, J. A., Preece, P. E., Andreotti, P. E. & Bruckner, H. W. (1996). Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs, 7: 630–635.
Cree, I. A. & Kurbacher, C. M. (1997). Individualising chemotherapy for solid tumours – is there any alternative? Anti-Cancer Drugs 8: 541–548.
Foss, A. J. & Dolin, P. J. (1996). Trends in eye cancer mortality among adults in the USA and England and Wales. Br J Cancer, 74: 1687–1689.
Foss, A. J. E., Alexander, R. A., Jefferies, L. W., Hungerford, J. L., Harris, A. L. & Lightman, S. (1996). Microvessel count predicts survival in uveal melanoma. Cancer Res, 56: 2900–2903.
Hunter, E. M., Sutherland, L. A., Cree, I. A., Dewar, J. A., Preece, P. E. & Andreotti, P. E. (1993). Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol, 19: 242–249.
Iwasaki, H., Huang, P., Keating, J. & Plunkett, W. (1997). Differential incorporation of Ara-C, gemcitabine and fludarabine into replicating and repairing DNA in proliferating human leukaemia cells. Blood, 90: 270–278.
Kurbacher, C. M., Bruckner, H. W., Cree, I. A., Kurbacher, J. A., Wilhelm, L., Poch, G., Indefrei, D., Mallman, P., Krebs, D. & Andreotti, P. E. (1997). Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res, 3: 1527–1533.
Kurbacher, C. M., Cree, I. A., Bruckner, H. W., Mallmann, P. & Andreotti, P. E. (1998). Chemotherapy directed by the ATP tumour chemosensitivity assay improves response rates and survival for patients with recurrent ovarian cancer. Anti-Cancer Drugs, 9: 51–57.
Myatt, N., Cree, I. A., Kurbacher, C. M., Foss, A. J. E., Hungerford, J. L. & Plowman, P. N. (1997). The ex vivo chemosensitivity profile of choroidal melanoma. Anti-Cancer Drugs, 8: 756–762.
Peters, G. J., Ruiz van Haperen, V. W., Bergman, A. M., Veerman, G., Smitskamp-Wilms, E., van Moorsel, C. J., Kuiper, C. M. & Braakhuis, B. J. (1996). Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol, 23(suppl 10): 16–24.
Petty, R. D., Sutherland, L. A., Hunter, E. M. & Cree, I. A. (1995). Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin, 10: 29–34.
Plunkett, W., Huang, P. & Gandhi, V. (1995). Preclinical characteristics of gemcitabine. Anticancer Drugs, 6(suppl 6): 7–13.
Poch, G., Reiffenstein, R. J. & Unkelbach, H. D. (1990). Application of the isobologram technique for the analysis of combined effects with respect to additivity as well as independence. Can J Physiol Pharmacol, 68: 682–688.
Poch, G., Reiffenstein, R. J. & Baer, H. P. (1995). Quantitative estimation of potentiation and antagonism by dose ratios corrected for slopes of dose–response curves deviating from one. J Pharmacol Toxicol Methods, 33: 197–204.
Proebstle, T. M., Scheibenbogen, C., Sterry, W. & Keilholz, U. (1996). A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in ‘poor-risk’ metastatic melanoma. Eur J Cancer, 32A: 1530–1533.
Raivio, I. (1977). Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study. Acta Ophthalmol, 133(suppl): 1–64.
Thames Cancer Registry (1995). Cancer in south-east England 1992.
van Moorsel, C. J., Veerman, G., Bergman, A. M., Guechev, A., Vermorken, J. B., Postmus, P. E. & Peters, G. J. (1997). Combination chemotherapy studies with gemcitabine. Semin Oncol, 24: 17–23.
Author information
Authors and Affiliations
Additional information
aVinblastine used from 97M011 onwards
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Neale, M., Myatt, N., Cree, I. et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or Cytosine arabinoside. Br J Cancer 79, 1487–1493 (1999). https://doi.org/10.1038/sj.bjc.6690237
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690237
Keywords
This article is cited by
-
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo
Bulletin of Experimental Biology and Medicine (2020)
-
The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells
Tumor Biology (2014)
-
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike
Bone Marrow Transplantation (2012)
-
Medikamentöse Therapie des metastasierten Aderhautmelanoms
Der Onkologe (2006)
-
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients
British Journal of Cancer (2005)
